Talphera Nears Critical Trial Completion, Stock Poised to Jump
AI Prediction of Talphera, Inc. Common Stock (TLPH)
Talphera, a biopharmaceutical company, is poised for significant growth with its lead product candidate, Niyad, targeting CRRT anticoagulation. The ongoing NEPHRO-CRRT trial and upcoming PMA submission are key catalysts.
Talphera Inc. focuses on the development of Niyad for CRRT anticoagulation, a market with limited options. Currently in a pivotal trial, Niyad shows promise based on historical data and expert support. Completion of this trial and a successful PMA submission could significantly uplift Talphera's market value. The company's strategic execution, including trial site expansions and regulatory interactions, underscores its potential to meet upcoming milestones which could catalyze stock price growth in the near term.
TLPH Report Information
Prediction Date2026-04-02
Close @ Prediction$0.78
Mkt Cap9m
IPO Date2011-02-11
AI-derived Information
Recent News for TLPH
- Mar 25, 8:30 am — Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 (PR Newswire)
- Mar 23, 8:44 am — Talphera: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 23, 8:30 am — Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (PR Newswire)
- Mar 18, 4:05 pm — Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026 (PR Newswire)
- Mar 2, 8:30 am — Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial (PR Newswire)
- Nov 13, 12:00 am — Talphera Inc (TLPH) Q3 2025 Earnings Call Highlights: Strategic Investments and Regulatory ... (GuruFocus.com)
- Nov 12, 4:23 pm — Talphera: Q3 Earnings Snapshot (Associated Press Finance)
- Nov 12, 4:05 pm — Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
- Nov 5, 4:05 pm — Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025 (PR Newswire)
- Oct 21, 8:30 am — Talphera Announces the Appointment of Joe Todisco to Board of Directors (PR Newswire)
- Sep 8, 8:30 am — Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market (PR Newswire)
- Aug 26, 8:35 am — Talphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trial (TipRanks)
NDAPR (News-Driven AI Prediction Revision) events for TLPH
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest